Navigation Links
Isis Reports Financial Results and Highlights for 2012
Date:2/28/2013

opportunities for significant near-term revenue from partnerships while we are also setting the stage for significant future revenue growth," said Elizabeth L. Hougen, chief financial officer of Isis. 

"In 2013, we are predicting another year of strong financial performance while continuing to advance our pipeline. Although we are planning to have more than a dozen drugs in later-stage clinical studies throughout the year, we are projecting only a slight increase in our 2013 spending compared to 2012. As such, we expect to end 2013 with a pro forma NOL in the mid $60 million range. We are also projecting to end the year with more than $325 million in cash. Our guidance is supported by our partnering successes in 2012. Because most drugs are not profitable in their first year of commercialization, and because it is too early in the year to predict the revenue trajectory of KYNAMRO, we are being conservative in our projections by not including KYNAMRO profit share revenue this year.  We are pleased with the significant investment Genzyme is making to ensure a successful KYNAMRO launch.  This investment should support strong revenue growth in the future.  We are fortunate to have Genzyme with its expertise in selling and marketing orphan drugs commercializing KYNAMRO and we look forward to providing updates throughout the year on KYNAMRO's commercial success," concluded Ms. Hougen.

Upcoming Key Milestones

  • Receive KYNAMRO marketing opinion from the European regulatory agency
  • Initiate a Phase 2/3 program of ISIS-SMNRx in infants with spinal muscular atrophy
  • Report clinical data on ISIS-SMNRx at the American Academy of Neurology meeting in March
  • Report clinical data on ISIS-CRPRx in patients with rheumatoid arthritis
  • Report clinical data on ISIS-APOCIIIRx in patients with high triglycerides
  • Financial Results
    All pro forma amounts refer
    '/>"/>

    SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. NxStage Reports Record Fourth Quarter and Full-Year 2012 Financial Results
    2. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
    3. Mylan Reports a 23% Increase in Fourth Quarter 2012 Adjusted Diluted EPS to $0.65
    4. HeartWare International Reports Fourth Quarter 2012 Revenue Of $32.7 Million; Full Year 2012 Revenue Of $110.9 Million
    5. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
    6. Kewaunee Scientific Reports Improved Results for Third Quarter
    7. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
    8. Questcor Reports Fourth Quarter and Full Year 2012 Results
    9. ResearchMoz: Global MRI Systems Market to 2018 - Technological Advancements, Increasing Number of Applications and Advent of MRI Compatible Pacemakers to Drive Future Growth - Market Research Reports
    10. United Therapeutics Corporation Reports 2012 Fourth Quarter and Annual Financial Results
    11. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... -- Commonwealth Cornerstone Group (CCG) today announced the completion of an ... help fund the expansion and consolidation of healthcare services provided ... . PHN is the largest federally qualified ... is the largest employer in Sharon,s ... Currently, PHN Sharon offers scattered services out of ...
    (Date:12/24/2014)... 24, 2014 Kinex Pharmaceuticals announced today that ... Roswell Park Cancer Institute. KX2-361 (KX02), a ... has shown potent inhibitory activity against a broad panel ... resistant to Temozolomide (T98G), the most widely used chemotherapy ... brain tumor mouse model, KX2-361 consistently clears brain tumors ...
    (Date:12/24/2014)... Trade Commission (ITC) issued its final decision in the case ... issued on December 23, the ITC ruled in favor of ... invalid. BMC President, James Xu called ... the ITC,s decision in this case. This victory for us ... beginning on the key patents in the case. ResMed chose ...
    Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
    ... R1626 into phase IIb study, called POLI 1 ... of Roche,s new,investigational drugs for chronic hepatitis C ... given in combination with,PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(TM) ... Association for the Study of the,Liver Disease (AASLD) ...
    ... MCLEAN, Va., Nov. 1 Science,Applications International Corporation ... awarded a contract extension by the National Institute ... and Infectious,Diseases (DMID), part of the National Institutes ... services. The seven-year cost-plus-fixed-fee contract has an ...
    Cached Medicine Technology:Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 2Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 3Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 4Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 5Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 6Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 7SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases 2
    (Date:12/26/2014)... (PRWEB) December 26, 2014 The Biofeedback ... place March 24-28, 2015 in Rome, Italy and is ... includes workshops on a wide variety of ... well as peak performance training in athletes. The scientific ... the world. , Biofeedback monitoring allows clients to see ...
    (Date:12/26/2014)... Pentec Health, Inc. number fourteen on ... Pennsylvania for 2014. The awards program, created in 2000, ... kind in the country. The program is a public/private ... Community and Economic Development, the Pennsylvania State Council of ... Penn Business Journal. , Charlie Wilson, Vice ...
    (Date:12/25/2014)... December 26, 2014 This is a ... the global Sterilizers industry with a focus on the ... market status of the Sterilizers manufacturers and is a ... individuals interested in the industry. This report provides a ... and manufacturing technology. In this part, the report presents ...
    (Date:12/25/2014)... 25, 2014 Product liability lawsuits filed ... recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in ... Order issued in the U.S. District Court, Northern District ... an open conference on January 7, 2015, at the ... in West Palm Beach, Florida. The Conference is scheduled ...
    (Date:12/25/2014)... The short film “Color of Honor” by young director/producer ... true 9/11 hero, Welles Remy Crowther. It has been chosen ... of Nuremberg International Short Film Festival and the 8th International ... and director Luciana Lagana plays the mother of the ... Gregory Graham - Graham plays a heroic policeman ...
    Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
    ... Says NCPA Study, DALLAS, Sept. 27 The ... so rapidly that these benefits,are now the fastest rising ... the rate of retirement benefits, according to a new,analysis ... a separate,study also released today, the NCPA says Chile,s ...
    ... gene variants that convey risk for schizophrenia affect apparently healthy ... may have different versions of these genes, called alleles. ... end up with schizophrenia, this does not mean they are ... the largest study of its kind to date, scheduled for ...
    ... Paramount Acquisition,Corp. (OTC Bulletin Board: PMQC, PMQCU, ... the filing of a third,amendment to the preliminary ... that was originally filed on June 18, 2007. ... meeting of,stockholders to be held to consider the ...
    ... Calif., Sept. 27 With cold and flu,season ... infants and toddlers,will soon be visiting their family ... most cases, children suffering from ear infections,are prescribed ... infection,but when antibiotics fail to stop ear infections ...
    ... to women worried about whether getting pregnant after cancer ... by Norwegian scientists, presented today (Thursday) at the European ... almost all types of cancer, the survival of women ... after being treated for the disease is no different ...
    ... NEWBERG, Ore., Sept. 27 A team of internationally,recognized ... spa,that will open in the spring of 2009 along ... northeast Newberg. Joan Austin, president of Springbrook Properties, ... Beach, Fla., will oversee,development of what is destined to ...
    Cached Medicine News:Health News:Disability System Sorely in Need of Reform 2Health News:Disability System Sorely in Need of Reform 3Health News:Schizophrenia candidate genes affect even healthy individuals 2Health News:Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx 2Health News:Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx 3Health News:Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx 4Health News:Antibiotics Not Always Best Bet for Battling Childhood Ear Infections 2Health News:Study indicates pregnancy does not harm chances of survival from cancer 2Health News:International Consulting Firm Health Fitness Dynamics Hired to Oversee Springbrook Inn's Planned New Spa 2Health News:International Consulting Firm Health Fitness Dynamics Hired to Oversee Springbrook Inn's Planned New Spa 3
    ... The TOPCON ALE-3600 and ... assure perfectly fit lenses ... and with the convenience ... These lens edgers are ...
    Inquire...
    ... have two choices for finishing. The first choice ... wholesale lab, which meant longer delay to deliver ... order in house, but that meant a substantial ... inventory, more space and employee training. TOPscan Remote ...
    ... Ergonomic, computer-integrated, flexibility, combined with the ... contemporary styling, make the new Topcon ... highly competitive 21st Century practice environments: ... lane fits comfortably in an 8' ...
    Medicine Products: